Multiparametric flow cytometry has excellent prediction for survival among patients with B-cell acute lymphoblastic leukemia<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, Dec. 21, 2022 (HealthDay News) — A single-tube eight-color multiparametric flow cytometry (MFC) panel has good sensitivity for minimal\/measurable residual disease (MRD) and excellent prediction for survival among patients with B-cell acute lymphoblastic leukemia (B-ALL), according to a study published online Dec. 12 in the Archives of Pathology & Laboratory Medicine<\/em>.<\/p>\n Hongyan Liao, Ph.D., from the West China Hospital of Sichuan University in Chengdu, and colleagues reported their experience using a single-tube eight-color MFC panel to measure MRD status in adult B-ALL patients. The characteristics, MRD status, and prognosis of 486 patients were analyzed during a 10-year period.<\/p>\n The researchers found that in 74.2 percent of cases, MRD as assessed by MFC and polymerase chain reaction assays for BCR-ABL+<\/sup><\/em> patients were concordant. MRD-negative status by MFC panel predicted favorable relapse-free survival and overall survival at the end of induction and the end of one consolidation course. Compared with those with at least one MRD-positive result and continuous MRD-positive results, patients with continuous MRD-negative results and at least one MRD-negative result showed favorable relapse-free survival and overall survival.<\/p>\n “Our single-tube eight-color MFC could potentially be taken as a routine indicator in the evaluation of the treatment response for adult patients with B-ALL,” the authors write.<\/p>\n